Eli Lilly and Company (LLY) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Eli Lilly and Company financial statements at a glance

Eli Lilly and Company reported revenue of $65.18 billion for fiscal year 2025 (ended December 31, 2025), up 44.7% from fiscal year 2024. Net income was $20.64 billion, a net margin of 31.7%, and diluted earnings per share were $22.95.

At the end of fiscal year 2025 it had total assets of $112.48 billion, total liabilities of $85.94 billion and shareholders' equity of $26.54 billion, with cash and short-term investments of $7.27 billion and total debt of $42.50 billion.

Its operations brought in $16.81 billion of cash; capital spending was $10.85 billion, leaving free cash flow of $5.96 billion.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

LLY logo

Eli Lilly and Company

LLYUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
65.18B
Prev Year: 45.04B
YoY: +44.7%
Operating Revenue
65.18B
Prev Year: 45.04B
YoY: +44.7%
Tax Effect of Unusual Items
-671.52M
Prev Year: -691.43M
YoY: +2.9%
Write-offs
484.00M
Prev Year: 425.60M
YoY: +13.7%
Cost of Revenue
11.05B
Prev Year: 8.42B
YoY: +31.3%
Gross Profit
54.13B
Prev Year: 36.62B
YoY: +47.8%
Operating Expense
24.43B
Prev Year: 19.12B
YoY: +27.8%
Selling General and Administrative
11.09B
Prev Year: 8.13B
YoY: +36.4%
Research and Development
13.34B
Prev Year: 10.99B
YoY: +21.3%
Operating Income
29.70B
Prev Year: 17.50B
YoY: +69.7%
Other Income Expense
-3.96B
Prev Year: -4.22B
YoY: +6.0%
Net Non Operating Interest Income Expense
-
Prev Year: -605.40M
Special Income Charges
-3.39B
Prev Year: -4.14B
YoY: +18.0%
Non-operating Interest Income
-
Prev Year: 175.20M
Restructuring and Mergers Acquisition
2.91B
Other Non-operating Income (expense)
-571.00M
Prev Year: -25.40M
YoY: -2148.0%
Non-operating Interest Expense
-
Prev Year: 780.60M
Pre-tax Income
25.73B
Prev Year: 12.68B
YoY: +102.9%
Provision for Income Taxes
5.09B
Prev Year: 2.09B
YoY: +143.5%
Net Income Common Stockholders
20.64B
Prev Year: 10.59B
YoY: +94.9%
Net Income
20.64B
Prev Year: 10.59B
YoY: +94.9%
Net Income Including Non-Controlling Interests
20.64B
Prev Year: 10.59B
YoY: +94.9%
Net Income from Continuing Operations
20.64B
Prev Year: 10.59B
YoY: +94.9%
Diluted NI Available to Com Stockholders
20.64B
Prev Year: 10.59B
YoY: +94.9%
Basic EPS
23
Prev Year: 11.76
YoY: +95.6%
Diluted EPS
22.95
Prev Year: 11.71
YoY: +96.0%
Weighted Average Shares (basic)
897.30M
Prev Year: 900.61M
YoY: -0.4%
Weighted Average Shares (diluted)
899.30M
Prev Year: 904.06M
YoY: -0.5%
Total Expenses
35.48B
Prev Year: 27.54B
YoY: +28.8%
Net Income from Continuing and Discontinued Operation
20.64B
Prev Year: 10.59B
YoY: +94.9%
Normalized Income
23.36B
Prev Year: 14.09B
YoY: +65.8%
EBIT
29.70B
Prev Year: 13.46B
YoY: +120.6%
EBITDA
31.69B
Prev Year: 15.23B
YoY: +108.1%
Interest Income
-
Prev Year: 175.20M
Reconciled Cost of Revenue
11.05B
Prev Year: 8.42B
YoY: +31.3%
Interest Expense
-
Prev Year: 780.60M
Reconciled Depreciation
2.00B
Prev Year: 1.77B
YoY: +13.0%
Net Interest Income
-
Prev Year: -605.40M
Net Income from Continuing Operation Net Minority Interest
20.64B
Prev Year: 10.59B
YoY: +94.9%
Total Unusual Items Excluding Goodwill
-3.39B
Prev Year: -4.19B
YoY: +19.0%
Total Unusual Items
-3.39B
Prev Year: -4.19B
YoY: +19.0%
Normalized EBITDA
35.09B
Prev Year: 19.42B
YoY: +80.7%
Tax Rate for Calcs
0.198
Prev Year: 0
Values in USD

Eli Lilly and Company key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$65.2B$45.0B$34.1B$28.5B$28.3B
Gross profit$54.1B$36.6B$27.0B$21.9B$21.0B
Operating income$29.7B$17.5B$10.8B$8.7B$7.9B
Net income$20.6B$10.6B$5.2B$6.2B$5.6B
Diluted EPS$22.95$11.71$5.80$6.57$5.85
Total assets$112.5B$78.7B$64.0B$49.5B$48.8B
Total liabilities$85.9B$64.4B$53.1B$38.7B$39.7B
Shareholders' equity$26.5B$14.2B$10.8B$10.6B$9.0B
Cash and short-term investments$7.3B$3.4B$2.9B$2.2B$3.9B
Total debt$42.5B$33.6B$25.2B$16.2B$16.9B
Operating cash flow$16.8B$8.8B$4.2B$7.6B$7.4B
Capital spending$10.8B$8.4B$7.4B$3.0B$2.0B
Free cash flow$6.0B$414.3M-$3.2B$4.6B$5.4B

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Eli Lilly and Company's revenue in fiscal year 2025?

$65.18 billion, up 44.7% from $45.04 billion in fiscal year 2024.

How much profit does Eli Lilly and Company make?

Eli Lilly and Company reported net income of $20.64 billion for fiscal year 2025 (31.7% of revenue); operating income was $29.70 billion.

How much cash and debt does Eli Lilly and Company have?

At the end of fiscal year 2025: cash and short-term investments of $7.27 billion and total debt of $42.50 billion.

What is Eli Lilly and Company's free cash flow?

$5.96 billion in fiscal year 2025 (operating cash flow of $16.81 billion minus capital spending of $10.85 billion).

MoreEli Lilly and Company stock overviewEli Lilly and Company executive teamEli Lilly and Company shareholdersEli Lilly and Company revenue by segment
RelatedPharmaceutical Preparation Manufacturing industryManufacturing sectorNovo Nordisk A/S financialsOramed Pharmaceuticals (ORMP)Biomea Fusion (BMEA)Vicapsys Life Sciences (VICP)
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
© 2026 DataPorium. All rights reserved.|About & MethodologyPrivacy PolicyTerms of Use
LinkedInLinkedInXXYouTubeYouTube